



Enzyme
B I O S Y S T E M S

OTC-BB STOCK SYMBOL: ENZB EXECUTIVE SUMMARY

EnzymeBioSystems (“ENZB”), a Nevada corporation, was founded on June 26, 2009, for the purpose of utilizing enzyme technologies to develop commercial solutions for a broad range of applications within the specialty chemical industry. Enzymes can be categorized as “enzyme inhibitors” and “enzyme activators.” Enzyme inhibitors are molecules that bind to enzymes and decrease their activity. Since blocking an enzyme’s activity can kill a pathogen or correct a metabolic imbalance, many drugs are enzyme inhibitors. Enzyme activators are molecules that bind to enzymes and increase their activity. These molecules are often involved in the allosteric [defined as having to do with a protein with a structure that is altered reversibly by a small molecule so that its original function is modified] regulation of enzymes in the control of metabolism. Both enzyme inhibitors and enzyme activators are currently used by many pharmaceutical and biotechnology companies in research and development of new drug compounds.

BACKGROUND

Mr. Ashot Martirosyan, a founder of the Company was the head of the “Anti-Biotics and Enzyme Inhibitors Laboratory” of “Institute of Organic Chemistry” in Yerevan, Armenia, until November 2008. He was born in the country of Armenia moved to USA in November 2008 and started preparing his research results and scientific materials for publications. In 1984, Mr. Martirosyan received his Ph.D. degree from

Yerevan State University as a Candidate of Chemical Sciences: Organic Chemistry.

During the course of ENZB's research and development activities, and based on research published by Mr. Martirosyan in Europe, the Company improved a semi-synthetic penicillin and cephalosporin containing fragments of sarcomycin, or an antitumor antibiotic. The Company has begun in vivo animal studies. These animal studies have produced some promising results. To this end, the Company is seeking financial and business partners necessary to execute its business plan and generate, in the short term, cash flow.

THE BUSINESS


EnzymeBioSystems was created to evaluate and develop enzyme compounds which management believes has a specific therapeutic value in fighting tumors. In July, 2010, ENZB entered into an agreement with Northeastern Ohio Universities College of Medicine d/b/a Northeastern Ohio Universities Colleges of Medicine and Pharmacy in Rootstown, Ohio, to perform in vivo animal studies. The research will study: 1) an examination of the in vitro cytotoxicity of penicillin analogs against hepatocellular carcinoma cells; and 2) Investigate the dose-responsive antitumor actions of penicillin analogs against chemically-induced hepatic tumorigenesis in rats. The purpose of this study is to obtain an Investigational New Drug Application ("IND") with the U. S. Food and Drug Administration, to begin evaluating anti-tumor antibiotic in human studies.

HIGHLIGHTS:

- **Developed antitumor antibiotic**
- **In vivo animal studies in progress, showing dramatic tumor reduction results**
- **Large market potential for antitumor antibiotics**
- **Strong upside potential for Company and its stock, and outright purchase of the Company**
- **Experienced, industry specific management team**

ANIMAL RESEARCH RESULTS


Demonstrated below are photos of a tumor being reduced in size following the treatment with ENZB's antitumor antibiotic:



This demonstrates the reduction of a tumor in a rat following three weeks ENZB's antitumor antibiotic:



Pathology Results:



Dramatic reduction in the number of cancer cells.

MANAGEMENT OBJECTIVES

Management's objectives include: 1) broaden the market exposure for the Company; 2) complete the necessary research to move its products into Phase I and Phase II (human testing); and 3) find a large pharmaceutical company to purchase/acquire the Company's technologies and products, within the next three (3) years.



ENZYMEBIOSYSTEMS STOCK DATA

Trading on OTC-Bulletin Board (Approval for listing: November 5, 2010)

Trading Symbol: ENZB

Original Filing Date of the S-1 Registration Statement: September 28, 2009; Effective December 18, 2009

Common Stock: 31,500,000 shares issued and outstanding.

Common Stock held by Officers: 20,000,000 shares

Common Stock in float: 11,500,000 shares

Common Stock Authorized: 195,000,000 shares

Preferred Stock Authorized: 5,000,000 shares

Preferred Stock issued: 1,000,000

Number of Shareholders: 39

Warrants and Options: None

CUSIP: 29414C102

MARKET SIZE

Breast cancer represents one of the most frequently diagnosed cancers and predominant cause of death in women worldwide. Every year, more than a million women are diagnosed with breast cancer, worldwide. Breast cancer is the most common type of cancer and second leading cause of death in women, only next to lung cancer. The global market for predictive breast cancer diagnostic and drug technologies was valued at \$21.2 billion in 2011. This market is expected to rise at a compound annual growth rate (CAGR) of 2.5% and reach \$24 billion by 2016. The market for breast cancer drugs reached \$10.2 billion in 2011. The market is expected to reach \$11.2 billion by 2016, a CAGR of 1.9%.

ENZYMEBIOSYSTEMS PRODUCTS

ENZB is focusing its efforts to develop innovative breast cancer drugs. ENZB has developed two separate products that show promise in effective treatment of breast cancer. These pharmaceutical products provide enhanced focus on tailored drug delivery in breast cancer treatment.

ENZB's first product is: a semisynthetic penicillin and cephalosporin containing structural fragments of the well-known antitumor antibiotic sarcomycin. This product was developed by ENZB's founder and underwent clinical trials and research in Russia, where the product showed excellent results in reducing the size of tumors. A provisional patent has been filed for this product.

ENZB's second product is: Amooranin, a triterpene acid with a novel structure isolated from the stem bark of *Amoora rohituka*, a tropical tree growing wild in India. Recent studies showed that multiple breast cancer cell lines respond to Amooranin in growth suppression assays. Mechanistic studies suggest that Amooranin suppresses growth factor signaling, induces cell cycle arrest, and promotes apoptosis. Because the anti-neoplastic activity of the plant-derived compound of Amooranin is relatively weak,

ENZB scientist developed a new analogue of this molecule by chemical transformations in an attempt to identify a more potent agent. One of these analogues, Amooranin-Me, was found to inhibit proliferation of several breast cancer cells with greater potency than the parent compound of Amooranin. Preliminary screening of Amooranin-Me in in vitro experiments revealed an astonishing potency against breast cancer MCF-7 cells with concentrations down to the nanomolar range. All these studies indicate that Amooranin-Me is a promising drug with potential to be used for human breast cancer prevention.

THE MANAGEMENT

Gary Rojewski, Chief Executive Officer

Gary Rojewski has 29-years experience in the pharmaceutical industry. During that time he has worked for Procter & Gamble Pharmaceuticals, Warner Chilcott Pharmaceuticals and most recently Actavis. Throughout his pharmaceutical career he has been responsible for commercializing pharmaceutical products.





Procter & Gamble Pharmaceuticals, Inc. (NYSE: PG)
Cincinnati, OH

1982 - 1991 Sales Representative marketing pharmaceutical products.
1991 - 1997 Sales Manager managing the sales organization.
1997 - 2005 Director manager care operations.
2005 - 2010 Director of managed care division

Warner Chilcott Pharmaceuticals, Inc. (NYSE: WCRX)
Rockaway, New Jersey

2010 - 2012 Director of managed care division (responsible for commercializing pharmaceutical products)

Warner Chilcott Pharmaceuticals, Inc. (NYSE: WCRX) purchased the pharmaceutical division of Procter & Gamble Pharmaceuticals in February 2010.

Actavis (NYSE: ACT)
Parsippany, NJ 07054

2012 - March 31, 2014 (date of announced retirement) Director of managed care division (responsible for commercializing pharmaceutical products).

Activis acquired **Warner Chilcott PLC** on October 1, 2013, creating an \$11 billion specialty pharmaceutical company.

Personal Information:

Married
Age: 60
Good Health

THE MANAGEMENT

Ashot Martirosyan, Science Officer

Mr. Martirosyan was the head of the “Anti-Biotics and Enzyme Inhibitors Laboratory” of “Institute of Organic Chemistry” in Yerevan, Armenia until November 2008. He moved to USA November 2008 and started preparing his research results and scientific materials for publications.

Mar. 2009 –Present, President and Director of EnzymeBioSystems.

1992 - 2008 Institute of Fine Organic Chemistry,
National Academy of Sciences, Republic of Armenia
Head of Antibiotics Laboratory

1984 - 1992 Institute of Fine Organic Chemistry,
National Academy of Sciences, Republic of Armenia
Senior Researcher

1976 - 1984 Institute of Fine Organic Chemistry,
National Academy of Sciences, Republic of Armenia
Antibiotics Laboratory Researcher

1974 - 1976 Optical-Mechanical Corporation - “Astro”
Head of Chemical Laboratory
Republic of Armenia

Education:

1980 - 1984 Yerevan State University
Ph.D. degree, Candidate of Chemical Sciences: Organic Chemistry

1969 - 1974 Moscow Chemical and Technological Institute of D.I. Mendeleev
Department of Organic Chemistry, Chemical Technology



Notes:

Some of the information contained herein has been prepared based upon assumptions about conditions and courses of action that management believes are reasonably possible. Information compiled on the basis of a set of different conditions and courses of action could differ substantially from those included herein. Readers of this information should be aware that some of the conditions and courses of action in management's initial assumptions will inevitably change to some degree as the business begins to take shape and operate.

THIS DOCUMENT CONTAINS SUMMARIES. SUCH SUMMARIES DO NOT PURPORT TO BE COMPLETE AND ARE QUALIFIED IN THEIR ENTIRETY BY REFERENCE TO THE TEXTS OF THE ORIGINAL DOCUMENTS, DATA AND OTHER INFORMATION THAT ARE AVAILABLE UPON REQUEST. IF DESCRIPTIONS OR TERMS IN THIS MEMORANDUM ARE INCONSISTENT OR CONTRARY TO DESCRIPTIONS OR TERMS IN SUCH AGREEMENTS OR DOCUMENTS, THEN THE FULL AGREEMENT OR DOCUMENT, AND NOT THE SUMMARY CONTAINED IN THIS MEMORANDUM, SHALL CONTROL.

CERTAIN OF THE INFORMATION CONTAINED HEREIN REPRESENTS OR IS BASED UPON FORWARD-LOOKING STATEMENTS OR INFORMATION. THE COMPANY BELIEVES THAT SUCH STATEMENTS AND INFORMATION ARE BASED UPON REASONABLE ESTIMATES AND ASSUMPTIONS. HOWEVER, FORWARD-LOOKING STATEMENTS AND INFORMATION ARE INHERENTLY UNCERTAIN, AND FACTORS AND RISKS INCLUDING ECONOMIC, COMPETITIVE, GOVERNMENTAL AND TECHNOLOGICAL FACTORS AFFECTING OPERATIONS, PRODUCTS, SERVICES AND PRICES WHICH MAY CAUSE ACTUAL EVENTS OR RESULTS TO DIFFER FROM THOSE PROJECTED. THEREFORE, UNDUE RELIANCE SHOULD NOT BE PLACED ON SUCH FORWARD-LOOKING STATEMENTS AND INFORMATION.